Protara Therapeutics, Inc. Common Stock (TARA) is a publicly traded Healthcare sector company. As of May 21, 2026, TARA trades at $4.69 with a market cap of $258.54M and a P/E ratio of -3.52. TARA moved +9.91% today. Year to date, TARA is -11.69%; over the trailing twelve months it is +36.78%. Its 52-week range spans $1.60 to $10.48. Analyst consensus is strong buy with an average price target of $25.83. Rallies surfaces TARA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Protara to Unveil 12-Month Interim Data from 31-Patient Phase 2 Bladder Cancer Trial: Protara will present updated safety and efficacy data from 31 BCG-naïve non-muscle invasive bladder cancer patients in its Phase 2 ADVANCED-2 trial at the AUA Annual Meeting May 15–18 in Washington, DC. A separate poster will detail interim results for the BCG-unresponsive cohort following six weekly instillations and three-week maintenance of TARA-002.
| Metric | Value |
|---|---|
| Price | $4.69 |
| Market Cap | $258.54M |
| P/E Ratio | -3.52 |
| EPS | $-1.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.48 |
| 52-Week Low | $1.60 |
| Volume | 757 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-57.44M |
| Gross Margin | 0.00% |
7 analysts cover TARA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.83.